What You Should Know:
- CCS — leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — today announced PropheSee™ a new, AI-powered predictive model for healthcare organizations focused on improving adherence in the population of people that have been prescribed a continuous glucose monitoring (CGM) device to help manage their
Read More
Impact of Diabetes Management for Patients, Payers, and Providers| News, Policy, Analysis, Insights - HIT Consultant
Nearly 70% of High-Risk Patients Unaware of Chronic Kidney Disease Risk, Study Finds
What You Should Know:
- A new study by Phreesia and the National Kidney Foundation (NKF) reveals a troubling gap in awareness of chronic kidney disease (CKD) among high-risk patients. Published in The American Journal of Accountable Care, the research highlights the importance of patient-provider communication and patient activation in early detection and prevention of CKD, a leading cause of death in the United States.
- The research emphasizes the value of patient education and
Read More
Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM
What You Should Know:
- Tandem Diabetes Care announced today that its Tandem Mobi insulin pump is fully compatible with Dexcom G6 and Dexcom G7 Continuous Glucose Monitoring (CGM) systems.
- Tandem is now the only company offering two insulin pump options integrated with both Dexcom G6 and Dexcom G7 CGM systems. This choice empowers people with diabetes to select the best solution for their individual needs and preferences.
Tandem Mobi: A Compact and Effective
Read More
Tandem Mobi Integrates with Dexcom G7 CGM, Expanding Choice for Diabetes Management
What You Should Know:
- Tandem Diabetes Care (TNDM) and Dexcom (DXCM) announced today that the Tandem Mobi insulin pump with Control-IQ technology is now compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) systems.
- Overall, the Tandem Mobi and Dexcom G7 combination empowers people with diabetes with a discreet, convenient, and technologically advanced solution for managing their condition.
Tandem Mobi: Small Pump, Big Choice for Diabetes
Read More
Weekly Ozempic/Wegovy Injections May Lower Kidney Failure Risk, Study Finds
What You Should Know:
- A new study suggests that a weekly treatment with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may significantly reduce the risk of kidney failure and other complications in patients with type 2 diabetes and chronic kidney disease (CKD).Find semaglutide online today.
- Funded by Novo Nordisk creators of Ozempic and Wegovy semaglutide injections for diabetes management, the study published in The New England Journal of Medicine investigated
Read More
Remote Diabetes Monitoring: Senseonics Partners with Rimidi to Enhance Diabetes Care
What You Should Know:
- Senseonics Holdings, Inc., a provider of long-term implantable continuous glucose monitoring (CGM) systems, today announced a strategic partnership with Rimidi. Rimidi offers a comprehensive clinical management platform designed to improve chronic disease management for patients and healthcare providers.
- The collaboration aims to develop the Eversense® Remote Patient Monitoring (RPM) Program, which will integrate seamlessly with existing healthcare
Read More
MD Revolution & Dexcom Integrate Remote Glucose Monitoring
What You Should Know:
- MD Revolution, known for its remote care management solutions, collaborates with Dexcom to integrate cutting-edge continuous glucose monitoring systems into its platform.
- Dexcom, a global leader in real-time continuous glucose monitoring, serves over 537 million individuals worldwide living with diabetes. Through wearable devices synced with smartphones, patients' glucose data becomes accessible to clinicians via MD Revolution's care management platform,
Read More
Report Reveals Digital Diabetes Management Tools Fail to Deliver Benefits, Increase Costs
What You Should Know:
- Digital diabetes management tools are failing to deliver meaningful health benefits to patients, according to a new evaluation by the Peterson Health Technology Institute (PHTI).
- The report casts doubt on the effectiveness of widely used digital diabetes management tools. Despite billions in investment, the study finds these tools offer minimal health benefits and actually increase healthcare spending.
Millions Rely on Tools, But Evidence Shows Little
Read More
Know Labs Unveils KnowU: Wearable Non-Invasive CGM Poised to Revolutionize Glucose Monitoring
What You Should Know:
- Know Labs (NYSE American: KNW), a leading innovator in non-invasive medical diagnostic technology, today announced the unveiling of its KnowU™, a wearable, non-invasive continuous glucose monitor (CGM).
- With over 270 patents issued, pending, and in process, Know Labs has established a solid foundation for its technology, creating a competitive advantage in the non-invasive CGM landscape.
Wearable, Non-invasive Continuous Glucose Monitor
Just eight months
Read More
Medicare Expands Coverage for Eversense E3 CGM System, Offering More Options for Diabetes Management
What You Should Know:
- Medicare has significantly expanded access to the Eversense E3 continuous glucose monitoring (CGM) System, a long-lasting and implantable option that offers several advantages over traditional CGMs.
- Medicare has significantly expanded access to the Eversense E3 CGM System, the longest-lasting continuous glucose monitor available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal-only patients, by the first three
Read More
